New England Journal of Medicine Publishes Lupus Drug Trial Paper Authored by Oklahoma Medical Research Foundation Expert
March 18, 2022
March 18, 2022
OKLAHOMA CITY, Oklahoma, March 18 (TNSRes) -- The Oklahoma Medical Research Foundation issued the following news:
A clinical trial of a new treatment for lupus may offer hope to patients worldwide.
The highest dose of the investigational drug iberdomide showed a reduction of lupus symptoms by the end of a 24-week, Phase 2 study. Some of the data, if confirmed, suggests the possibility that a specific subset of patients with this complicated disease might be more likely . . .
A clinical trial of a new treatment for lupus may offer hope to patients worldwide.
The highest dose of the investigational drug iberdomide showed a reduction of lupus symptoms by the end of a 24-week, Phase 2 study. Some of the data, if confirmed, suggests the possibility that a specific subset of patients with this complicated disease might be more likely . . .